Track topics on Twitter Track topics that are important to you
Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019
Neuronal Acetylcholine Receptor Subunit Alpha 7 CHRNA7 pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 CHRNA7 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Neuronal Acetylcholine Receptor Subunit Alpha 7 CHRNA7 Neuronal acetylcholine receptor subunit alpha7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ionconducting channel across the plasma membrane. The channel is blocked by alphabungarotoxin. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 5 and 6 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology which include indications Alzheimer's Disease, Cognitive Impairment Associated With Schizophrenia CIAS, Schizophrenia, Bipolar Disorder Manic Depression, Pain, Parkinson's Disease, Smoking Cessation, Traumatic Brain Injury, Anxiety Disorders, Attention Deficit Hyperactivity Disorder ADHD, Cognitive Disorders, Cognitive Impairment, Complex Regional Pain Syndrome Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy, Dementia Associated With Alzheimer's Disease, Inflammation, Ischemic Stroke, Major Depressive Disorder, Neuropathic Pain Neuralgia, Obesity, Panic Disorders and PostTraumatic Stress Disorder PTSD.
Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 CHRNA7 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 CHRNA7
The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 CHRNA7 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 CHRNA7 targeted therapeutics and enlists all their major and minor projects
The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 CHRNA7 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 CHRNA7 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 CHRNA7
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 CHRNA7 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeNEXT ARTICLE
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...